Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the appointment of Maha Radhakrishnan, M.D. to the company’s board of directors. Dr. Radhakrishnan is an accomplished industry executive with decades of experience advancing large strategic portfolios across different therapeutic areas through product development and commercialization and overseeing the global medical strategy and operations within major biotechnology and pharmaceutical companies.

“Maha joins our Board at a pivotal moment for Alto, as we continue on our path and fulfill our ambition of redefining psychiatry with our precision pipeline in areas of persistent medical need,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto. “Throughout her distinguished career, Maha has been dedicated to advancing patient care through more personalized approaches to treatment. We believe her guidance and input will be invaluable as we work to make precision psychiatry a reality for patients, physicians, caregivers, and payers.”

Maha Radhakrishnan, M.D., recently served as group senior vice president and chief medical officer of Biogen, responsible for the worldwide medical function, until March 2024. Previously, Dr. Radhakrishnan was senior vice president and global head of medical, primary care business unit at Sanofi, a global biopharmaceutical company focused on human health. At Sanofi, she led the function providing the medical strategy for the diabetes and cardiovascular products and programs in development. Prior, she held several leadership roles at Bioverativ Inc., Bristol Myers Squibb, United Health Group, and Cephalon. Dr. Radhakrishnan received her M.D. in internal medicine with honors from the People’s Friendship University in Moscow, Russia in 1995, as well as a master's degree in Russian language.

“The emergence of precision psychiatry is critically important given the urgent need to address the disparities in individual responses across treatments in mental healthcare,” added Dr. Radhakrishnan. “I am honored to join Alto’s board at such an exciting time in the company’s journey and I am encouraged by the data that has been exhibited across the company’s programs to date. I believe successful stratification of patients can unlock the ability to redefine psychiatric care in a truly meaningful way and Alto’s Precision Psychiatry Platform has the potential to pioneer this transformation.”